| Id |
Subject |
Object |
Predicate |
Lexical cue |
| T172 |
0-98 |
Sentence |
denotes |
There are currently no approved antiviral treatments or vaccines for human coronavirus infections. |
| T173 |
99-274 |
Sentence |
denotes |
The development of safe, stable vaccines is a huge challenge and vaccines would ideally be broad-spectrum, so the research and development of new drugs is a very long process. |
| T174 |
275-391 |
Sentence |
denotes |
In such a sudden epidemic, scientists were not able to carry out new drug development by the traditional principles. |
| T175 |
392-541 |
Sentence |
denotes |
Therefore, there is another option: a systematic and large-scale screening of existing drugs to see whether they have activity against the 2019-nCoV. |
| T176 |
542-639 |
Sentence |
denotes |
Recently drug screening found that nelfinavir has potential antiviral activity against 2019-nCoV. |
| T177 |
640-755 |
Sentence |
denotes |
In addition, pitavastatin, perampanel, and praziquantel might also have moderate activities against 2019-nCoV [39]. |
| T178 |
756-922 |
Sentence |
denotes |
Based on previous studies, an anti-HIV drug named Kaletra may have therapeutic effect on SARS and MERS, which is composed of two protease inhibitors, ritonavir (CAS#: |
| T179 |
923-957 |
Sentence |
denotes |
155,213-67-5) and lopinavir (CAS#: |
| T180 |
958-1003 |
Sentence |
denotes |
192,725-17-0) [[40], [41], [42], [43], [44]]. |
| T181 |
1004-1141 |
Sentence |
denotes |
More recently, Kaletra was also recommended to treat Wuhan pneumonia by the National Health Commission of the People’s Republic of China. |
| T182 |
1142-1325 |
Sentence |
denotes |
Patients with SARS or MERS have used several drugs including ribavirin, interferon, lopinavir-ritonavir, and corticosteroids, but the efficacy of certain drugs is still controversial. |
| T183 |
1326-1652 |
Sentence |
denotes |
Other antiviral drugs, like FAD-approved drugs including ribavirin, penciclovir, nitrazine, nalfamusta, chloroquine, and the two broad-spectrum antiviral drugs redexivir (GS-5734) and favivir (T-705), are being evaluated by measuring the effects of these compounds on cytotoxicity, virus yield and infection rate of 2019-nCoV. |
| T184 |
1653-1832 |
Sentence |
denotes |
Recent results showed that remdesivir and chloroquine are effective in controlling 2019-nCoV infection in vitro and may be evaluated in human patients with 2019-nCoV disease [45]. |
| T185 |
1833-2025 |
Sentence |
denotes |
Remdesivir has recently been recognized as a promising antiviral drug against multiple RNA viruses (including SARS/MERS-CoV) in cultured cells, and in mouse and non-human primate (NHP) models. |
| T186 |
2026-2114 |
Sentence |
denotes |
Currently remdesivir for the treatment of Ebola virus infection is in clinical research. |
| T187 |
2115-2183 |
Sentence |
denotes |
It is promising that these compounds can treat 2019-nCoV infections. |
| T188 |
2184-2351 |
Sentence |
denotes |
Moreover, the fifth edition of infection prevention and control (IPC) guidance announced that severe and critically ill patients could be treated with recovery plasma. |
